Azitra announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secondary and exploratory endpoints assessing efficacy signals and biomarkers. Azitra expects to report interim safety data from the Phase 1b trial in early 2025 with full results anticipated in the second half of 2025. “Dosing the first patient in our Phase 1b trial of ATR-12 marks a vital milestone for Azitra and for patients suffering from Netherton syndrome,” said Francisco Salva, CEO of Azitra. “We are exhilarated to start dosing patients and look forward to executing this trial and delivering clinical data.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZTR:
- Azitra gets FDA clearance for IND to treat skin rash from EGFR inhibitors
- Azitra says first patient screened, scheduled to enroll in ATR-12 trial
- Azitra 6.67M share Secondary priced at $1.50
- USPTO grants Azitra patent for future potential pipeline candidates for AD
- Azitra files to sell 3.11M units on a ‘best efforts basis’